secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0000950170-24-057927
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences Q1 net loss $2.7M; cash $14.6M sufficient through 2024
-----------------------------------------------------------------------------

- Net loss of $2.7M ($2.46 per share) for Q1 2024, compared to net earnings of $6.2M in Q1 2023, driven by change in warrant liability.
- Cash and cash equivalents $14.6M as of March 31, 2024, up from $12.0M at December 31, 2023.
- Net cash used in operating activities was $2.8M, up from $1.6M YoY, due to clinical study expenses for GEM-AKI and GEM-SSI.
- Company believes current cash is sufficient to fund operations through 2024 based on current projections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024057927/0000950170-24-057927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024057927/revb-20240510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-057927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer